Meta bolis mand mitochon driain polycy stick idney disease

 X.Zhang,etal. Cancer Letters 481 (2020) 32–44 (2015) 388–395. [45] W. Lu, Y. Kang, Epithelial-mesenchymal plasticity in cancer progression and me- [33] F. Negoita, J. Blomdahl, S. Wasserstrom, M.E. Winberg, P. Osmark, S. Larsson, tastasis, Dev. Cell 49 (2019) 361–374. K.G.Stenkula,M.Ekstedt,S.Kechagias,C.Holm,H.A.Jones,PNPLA3variantM148 [46] X. Zheng, J.L. Carstens, J. Kim, M. Scheible, J. Kaye, H. Sugimoto, C.C. Wu, causes resistance to starvation-mediated lipid droplet autophagy in human hepa- V.S. LeBleu, R. Kalluri, Epithelial-to-mesenchymal transition is dispensable for tocytes, J. Cell. Biochem. 120 (2019) 343–356. metastasis but induces chemoresistance in pancreatic cancer, Nature 527 (2015) [34] V. Tesori, A.C. Piscaglia, D. Samengo, M. Barba, C. Bernardini, R. Scatena, 525–530. A. Pontoglio, L. Castellini, J.N. Spelbrink, G. Maulucci, M.A. Puglisi, G. Pani, [47] J. Chen, R. Jin, J. Zhao, J. Liu, H. Ying, H. Yan, S. Zhou, Y. Liang, D. Huang, A. Gasbarrini, The multikinase inhibitor Sorafenib enhances and sy- X. Liang, H. Yu, H. Lin, X. Cai, Potential molecular, cellular and microenviron- nergizes with glycolysis blockade for cancer cell killing, Sci. Rep. 5 (2015) 9149. mental mechanism of sorafenib resistance in hepatocellular carcinoma, Canc. Lett. [35] X.S. Chen, L.Y. Li, Y.D. Guan, J.M. Yang, Y. Cheng, Anticancer strategies based on 367 (2015) 1–11. the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect, [48] Y.Xu,H.Xu,M.Li,H.Wu,Y.Guo,J.Chen,J.Shan,X.Chen,J.Shen,Q.Ma,J.Liu, Acta Pharmacol. Sin. 37 (2016) 1013–1019. M. Wang, W. Zhao, J. Hong, Y. Qi, C. Yao, Q. Zhang, Z. Yang, C. Qian, J. Li, [36] J. Li, D. Cheng, M. Zhu, H. Yu, Z. Pan, L. Liu, Q. Geng, H. Pan, M. Yan, M. Yao, KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular car- OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the cinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition AKT/mTORsignalingpathwayinnon-smallcelllungcancer 3X FLAG Peptide,Theranostics9(2019) program, Canc. Lett. 454 (2019) 78–89. 179–195. [49] A. Forner, M. Reig, J. Bruix, Hepatocellular carcinoma, Lancet 391 (2018) [37] V.Padovano,C.Podrini,Metabolismandmitochondriainpolycystickidneydisease 1301–1314. 

research and therapy, Nat. Rev. Nephrol. 14 (2018) 678–687. [50] R.J. Gillies, I. Robey, R.A. Gatenby, Causes and consequences of increased glucose [38] M. Alvarez-Tejado, S. Naranjo-Suarez, C. Jimenez, A.C. Carrera, M.O. Landazuri, metabolism of cancers, J. Nucl. Med. 49 (Suppl 2) (2008) 24s–42s. L.delPeso,Hypoxiainducestheactivationofthephosphatidylinositol3-kinase/Akt [51] G. Pani, T. Galeotti, P. Chiarugi, Metastasis: cancer cell\'s escape from oxidative cell survivalpathwayinPC12 cells:protectiveroleinapoptosis Veratridine,J.Biol.###http://www.glpbio.com/simage/GA11366-H-D-Leu-Thr-Arg-pNA-acetate-salt-2.png####Chem.276 stress, Canc. Metastasis Rev. 29 (2010) 351–378. (2001) 22368–22374. [52] S. Kamarajugadda, L. Stemboroski, Q. Cai, N.E. Simpson, S. Nayak, M. Tan, J. Lu, [39] E.Y. Chen, N.M. Mazure, J.A. Cooper, A.J. Giaccia, Hypoxia activates a platelet- Glucose oxidation modulates anoikis and tumor metastasis, Mol. Cell Biol. 32 derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that (2012) 1893–1907. 

resultsinglycogensynthasekinase-3inactivation,Canc.Res.61(2001)2429–2433. [53] M.A.Huber,N.Kraut Cell Counting Kit-8 chemicals,H.Beug,Molecularrequirementsforepithelial-mesenchymal [40] I.Vivanco,C.L.Sawyers,Thephosphatidylinositol3-KinaseAKTpathwayinhuman transition during tumor progression, Curr. Opin. Cell Biol. 17 (2005) 548–558. cancer, Nat. Rev. Canc. 2 (2002) 489–501. [54] M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg [41] H. Zhang, H. Lu, L. Xiang, J.W. Bullen, C. Zhang, D. Samanta, D.M. Gilkes, J. He, effect: the metabolic requirements of cell proliferation, Science 324 (2009) G.L. Semenza, HIF-1 regulates CD47 expression in breast cancer to promote 1029–1033. evasionofphagocytosisandmaintenanceofcancerstemcells,Proc.Natl.Acad.Sci. [55] B. Bhattacharya, M.F. Mohd Omar, R. Soong, The Warburg effect and drug re- U. S. A. 112 (2015) E6215–E6223. sistance, Br. J. Pharmacol. 173 (2016) 970–979. [42] A.C. Martinez-Torres, C. Quiney, T. Attout, H. Boullet, L. Herbi, L. Vela, S. Barbier, [56] M.Tomizawa,F. Shinozaki,Y.Motoyoshi,T.Sugiyama,S.Yamamoto,N. Ishige,2- D. Chateau, E. Chapiro, F. Nguyen-Khac, F. Davi, M. Le Garff-Tavernier, Deoxyglucose and sorafenib synergistically suppress the proliferation and motility R. Moumne, M. Sarfati, P. Karoyan, H. Merle-Beral, P. Launay, S.A. Susin, CD47 of hepatocellular carcinoma cells, Oncol Lett 13 (2017) 800–804. agonist peptides induce programmed cell death in refractory chronic lymphocytic [57] R. Reyes, N.A. Wani, K. Ghoshal, S.T. Jacob, T. Motiwala, Sorafenib and 2-deox- leukemiaBcellsviaPLCgamma1activation:evidencefrommiceandhumans,PLoS yglucose synergistically inhibit proliferation of both sorafenib-sensitive and -re- Med. 12 (2015) e1001796. sistant HCC cells by inhibiting ATP production, Gene Expr. 17 (2017) 129–140. [43] F.Han,C.F.Li,Z.Cai,X.Zhang,ThecriticalroleofAMPKindrivingAktactivation [58] S. Li, W. Dai, W. Mo, J. Li, J. Feng, L. Wu, T. Liu, Q. Yu, S. Xu, W. Wang, X. Lu, under stress, tumorigenesis and drug resistance, Nat. Commun. 9 (2018) 4728. Q. Zhang, K. Chen, Y. Xia, J. Lu, Y. Zhou, X. Fan, L. Xu, C. Guo, By inhibiting [44] S.M. Jeon, N.S. Chandel, N. Hay, AMPK regulates NADPH homeostasis to promote PFKFB3,aspirinovercomessorafenibresistanceinhepatocellularcarcinoma,Int.J. tumour cell survival during energy stress, Nature 485 (2012) 661–665. Canc. 141 (2017) 2571–2584.

Comments

Post a Comment

Popular posts from this blog

32–44 significance and clinical application prospects

 X.Zhang,etal. Cancer Letters 481 (2020) 32–44 significance and clinical application prospects. purified using a HisTrap HP Ni sepharose (GE Healthcare Life Staphylococcalsuperantigen-likeprotein6(SSL6)isthefirstandthe Sciences, Beijing, China) with the user instructions and identified by only identified bacteria-derived protein that binds CD47 to date ITF2357 (Givinostat) . It has immunoblot with anti-His antibodies. The molecular weight was cal- been reported to promote macrophage phagocytosis by competitively culated by DNASTAR 12.1 software (Woodruff Health Sciences Center binding to CD47 [29]. However, its direct effect on tumor cells is un- Library) according to the amino sequence of His-tag labeled SSL6. clear.SinceCD47canregulatetheproliferationandapoptosisoftumor Recombinant protein was treated with Detoxi-Gel endotoxin removing cells [30 3x FLAG inhibitor ,31], and mediate the tolerance of HCC cells to SFN [13], we gel (Thermo Fisher Scientific, Waltham, MA, USA)
Read more

Contents lists available at ScienceDirect Cancer Letters journal homepage

 Cancer Letters 477 (2020) 107–121 Contents lists available at ScienceDirect Cancer Letters journal homepage: www.elsevier.com/locate/canlet Original Articles Dysbindin promotes pancreatic ductal adenocarcinoma by T activating NF-κB/MDM2 via miR-342–3p a,1 a,1 b,1 c a a a DonglieZhu ,ShiZheng ,ChengFang ,XinGuo ,DandanHan ,MingyaoTang ,HangFu , d e d,∗∗ f,∗∗∗ a,∗ Mingzuo Jiang , Ning Xie , Yongzhan Nie , Xuebiao Yao , Yong Chen a Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi\'an, Shaanxi, 710032, China b Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China c Department of Endoscopic Surgery, 986th Military Hospital, Fourth Military Medical University, Xi\'an, Shaanxi, 710054, China d State Key Laboratory of Cancer Biology 3xFLAG PEPTIDE glpbio , National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical Univer
Read more

in non-small cell lung cancer confers significant stage-independent survival dis- Expression of novel molecules

 W. Zhou, et al. Cancer Letters 483 (2020) 75–86 [35] 2016Alzheimer\'sdiseasefactsandfigures.AlzheimersDement.12(2016)459-509. Hernandez, PTENand PI3K/AKT in non-small-cell lung cancer, Pharmacogenomics [36] M. Reck, D.F. Heigener, T. Mok, J.C. Soria, K.F. Rabe, Management of non-small- 16 (2015) 1843–1862. cell lung cancer: recent developments, Lancet 382 (2013) 709–719. [45] O.David,H.LeBeau,A.R.Brody,M.Friedman,J.Jett,Phospho-Aktoverexpression [37] S. Ashida, M. Furihata, T. Katagiri, K. Tamura, Y. Anazawa, H. Yoshioka, et al., in non-small cell lung cancer confers significant stage-independent survival dis- Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), in- advantage, Chest 125 (2004) 152S. creaseswithhighGleasonscoreandprostatecancerprogression,Clin.Canc.Res.12 [46] S.Wang,Y.Zheng,Z.He,W.Zhou,Y.Cheng,C.Zhang,SH2B1promotesNSCLCcell (2006) 2767–2773. proliferation through PI3K/Akt/mTOR signaling cascade, Canc. Cell Int. 18 (2018) [38] E.
Read more